Get 50% OFF This Monsoon!
Zenotech Laboratories
No Data Available
No Stocks
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
No Research Report
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
No Data Available
Unlock Management Data
See Detailed Analysis & Insights
Zenotech Laboratories Limited (Formerly Sunline Technologies Limited) was established in June, 1989. The Company is a pharmaceutical specialty generic injectables company engaged in the area of manufacturing biotechnology products. The Company's injectables product portfolio primarily serves niche therapy areas like oncology and anesthesiology.
During financial year 2004-05, the Hon'ble High Court of Andhra Pradesh sanctioned the Scheme of Amalgamation with M/s. Zenotech Technologies Limited with effect from November 1st , 2003. The Company had issued 91,82,500 equity shares to erstwhile shareholders of M/s. Zenotech Laboratories Pvt. Ltd. and resultant, the name of Company was changed to 'Zenotech Laboratories Ltd.' with effect from August 10, 2004.
M/s, Credence Pharmaceuticals Limited and M/s, Hemarus Healthcare Private Limited were merged with the Company, on May 2, 2006 through Scheme of Amalgamation, effective from October 1, 2005. 15 generic chemical oncology products were launched by the Company in India. Besides, the Company launched its anesthesia range of products during 2006.
Consequent to the consummation of the merger of Ranbaxy Laboratories Limited into SPIL on March 24, 2015, SPIL indirectly acquired 46.84 percent of the voting rights held by Ranbaxy in, and control over the Company and became Promoter of the Company along with Daiichi Sankyo Company Limited and resultant, the Open Offer concluded in August 2015.
The Company started production from its newly commissioned Depot Injectable facility in FY 2019-20. It renovated its Biotech API manufacturing facility and the same was leased to Sun Pharmaceutical Industries Limited, for their R&D activities effective from July, 2021.
Zenotech Laboratories share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
Market capitalization of Zenotech Laboratories indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Zenotech Laboratories is valued compared to its competitors.
Zenotech Laboratories PE ratio helps investors understand what is the market value of each stock compared to Zenotech Laboratories 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
The PEG ratio of Zenotech Laboratories evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
Return on Equity (ROE) measures how effectively Zenotech Laboratories generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
Return on Capital Employed (ROCE) evaluates the profitability of Zenotech Laboratories in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
Total debt of Zenotech Laboratories shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
The Debt-to-Equity (DE) ratio of Zenotech Laboratories compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
CAGR shows the consistent growth rate of Zenotech Laboratories over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
Technical analysis of Zenotech Laboratories helps investors get an insight into when they can enter or exit the stock. Key components of Zenotech Laboratories Technical Analysis include:
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Zenotech Laboratories shares often struggle to rise above due to selling pressure.
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Zenotech Laboratories ’s financial health and profitability.
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
The financials of Zenotech Laboratories provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
The profit and loss statement of Zenotech Laboratories highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Zenotech Laboratories .
The balance sheet presents a snapshot of Zenotech Laboratories ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.
Download the App